Med2Date — Clinical Guidelines
Home Family Medicine Urinary Tract Infection

Urinary Tract Infection

Last updated 31 May 2026 · Urology / Infectious Disease

📋 Key Information Summary

📋
  • UTIs are among the most common bacterial infections managed in Australian primary care, accounting for over 100,000 hospitalisations annually and disproportionately affecting Aboriginal and Torres Strait Islander peoples.
  • UTI is a clinical masquerade — it can mimic pelvic inflammatory disease, appendicitis, prostatitis, renal colic, and in elderly patients may present solely as delirium, falls, or functional decline without classic urinary symptoms.
  • Classification is essential before treatment: asymptomatic bacteriuria (ASB), uncomplicated lower UTI (cystitis), upper UTI (pyelonephritis/urosepsis), catheter-associated UTI (CAUTI), and urethral syndrome each have distinct management pathways.
  • Asymptomatic bacteriuria requires treatment only in pregnancy and prior to urological procedures — do NOT treat in non-pregnant adults, catheterised patients, or the elderly.
  • Urine dipstick (nitrites and leucocyte esterase) has high negative predictive value in symptomatic, non-pregnant women; a negative result effectively excludes UTI in low-risk presentations.
  • Midstream urine (MSU) culture remains the gold standard; send specimens before commencing antibiotics in complicated UTI, pregnancy, treatment failure, recurrent infection, and all males.
  • First-line treatment for uncomplicated cystitis in non-pregnant adults is nitrofurantoin 50 mg PO BD for 5 days or trimethoprim 300 mg PO nocte for 3 days (check local resistance — avoid if resistance >20%).
  • Pregnant women with symptomatic UTI or ASB must be treated — amoxicillin 500 mg PO TDS or cephalexin 500 mg PO BD are first-line; nitrofurantoin is acceptable but avoid at term (≥36 weeks).
  • Children with UTI require urine culture confirmation, appropriate imaging for those <3 years or with atypical features, and should receive oral antibiotics for 7–10 days (trimethoprim or cephalexin).
  • Recurrent UTI (≥3 episodes in 12 months or ≥2 in 6 months) warrants investigation for underlying causes, behavioural modification counselling, and consideration of prophylactic low-dose antibiotics.
  • Antimicrobial resistance is rising nationally — ESBL-producing E. coli rates exceed 10% in many Australian regions; always consider local antibiograms and avoid empirical fluoroquinolones for uncomplicated UTI.
  • Aboriginal and Torres Strait Islander Australians experience 2–3 times higher UTI hospitalisation rates; culturally safe care, point-of-care testing in remote communities, and addressing housing and water access are critical.

Introduction & Australian Epidemiology

Urinary tract infection (UTI) encompasses a spectrum of clinical syndromes caused by microbial colonisation of the urinary tract, ranging from uncomplicated cystitis in healthy women to life-threatening urosepsis. UTIs are among the most frequently encountered infections in Australian general practice, affecting an estimated 150,000–200,000 Australians annually with a lifetime prevalence of approximately 50–60% in adult women.

The burden of UTI in Australia is substantial and inequitable. National Hospital Morbidity Database (AIHW) data consistently show UTI as a leading cause of potentially preventable hospitalisation, with rates highest among Aboriginal and Torres Strait Islander peoples, residents of remote areas, and the elderly. Antimicrobial consumption for UTI represents a significant proportion of total community antibiotic prescribing, making UTI management a key focus of antimicrobial stewardship initiatives under the National Antimicrobial Resistance Strategy (2020–2030).

⚠️
UTI as a masquerade: UTI may mimic or coexist with numerous conditions including pelvic inflammatory disease, appendicitis, diverticulitis, renal calculi, bladder malignancy, prostatitis, sexually transmitted infections, and vaginal infections. In older adults, UTI is frequently over-diagnosed as a cause of delirium, falls, and behavioural change, leading to inappropriate antibiotic use — always exclude other causes before attributing symptoms to UTI.
Epidemiological Feature Data
Lifetime prevalence in women 50–60% (at least one episode)
Annual incidence (women 18–65) ~80 per 1,000 women-years
Annual incidence (men) ~5–8 per 1,000 men-years
Hospitalisations (Australia, 2021–22) >100,000 separations per year
ATSI hospitalisation rate ratio 2.0–3.1× higher than non-Indigenous
Most common pathogen Escherichia coli (70–85%)
ESBL E. coli prevalence (community) 8–15% (varies by region; higher in SA/NSW)
Antimicrobial courses for UTI/year Estimated 2–3 million prescriptions nationally

Classification of Urinary Tract Infections

Accurate classification of UTI is essential because management, investigation requirements, and antimicrobial choices differ significantly between categories. A pragmatic classification framework is presented below.

Uncomplicated
Asymptomatic Bacteriuria (ASB)
Positive urine culture (≥10⁵ CFU/mL of a single organism) in a patient without urinary symptoms. Common in elderly, catheterised patients, and people with diabetes.
Treatment: Only in pregnancy and pre-urological procedure. Do NOT treat otherwise.
Uncomplicated
Acute Cystitis
Dysuria, frequency, urgency, suprapubic pain in a non-pregnant, pre-menopausal woman with no structural or functional urinary abnormality. Systemic features absent or minimal.
Setting: Primary care. Short-course oral antibiotics.
Complicated / Upper
Acute Pyelonephritis
Flank pain/costovertebral angle tenderness, fever ≥38°C, nausea/vomiting, with or without lower urinary tract symptoms. May occur in patients with structural/functional abnormalities.
Setting: GP (mild) or Emergency Department. Oral or IV antibiotics; consider admission.
Life-threatening
Urosepsis
UTI with sepsis criteria — systemic inflammatory response (tachycardia, tachypnoea, hypotension, altered mentation) secondary to urinary tract infection. May present with septic shock.
Setting: Emergency Department / ICU. IV broad-spectrum antibiotics, fluid resuscitation, critical care.
Category Key Features Population Treatment Urgency
Asymptomatic bacteriuria Positive culture, no symptoms Pregnant, elderly, catheterised, diabetic Treat only if pregnant or pre-procedure
Uncomplicated cystitis Dysuria, frequency, urgency; no systemic illness Non-pregnant, pre-menopausal women; no structural abnormality Outpatient — oral antibiotics, 3–5 days
Complicated cystitis Lower UTI symptoms in a patient with complicating factors (male, catheter, structural abnormality, immunosuppression) Males, catheterised, diabetes, anatomical abnormality Outpatient — culture-directed, 5–14 days
Acute pyelonephritis Fever, flank pain, CVA tenderness ± lower tract symptoms Any age/sex with ascending infection GP or ED — oral or IV, 7–14 days
Urosepsis UTI + SIRS/sepsis criteria Elderly, immunosuppressed, obstructed Emergency — IV antibiotics, fluid resuscitation, source control
Catheter-associated UTI (CAUTI) Symptoms attributable to UTI in catheterised patient (fever, new confusion, rigors); catheter in situ ≥48 h Inpatients, aged care, spinal cord injury Remove/replace catheter, culture-directed antibiotics 7–14 days
Urethral syndrome UTI-like symptoms with negative or low-count cultures; consider STI, interstitial cystitis, urethritis Women with recurrent symptoms and negative cultures Investigate alternative diagnoses; avoid empirical antibiotics
🚨
Urethral syndrome: Patients (typically women) presenting with classic UTI symptoms but consistently negative urine cultures should NOT receive repeated empirical antibiotics. Consider Chlamydia trachomatis urethritis, Mycoplasma genitalium, interstitial cystitis/bladder pain syndrome, urethral diverticulum, vaginal atrophy (postmenopausal), or functional pelvic floor disorders. Perform STI screening and consider specialist referral.

Laboratory Diagnosis

The diagnostic approach to UTI depends on the clinical context. For uncomplicated cystitis in otherwise healthy pre-menopausal women, empirical treatment without culture is often appropriate. In all other settings, urine culture remains the cornerstone of diagnosis and guides antimicrobial selection.

Urine Collection

A midstream urine (MSU) specimen is required for culture. In children who are not toilet-trained, suprapubic aspiration (SPA) is the gold standard; clean-catch urine is an acceptable alternative with appropriate technique coaching. In catheterised patients, obtain specimens from the sampling port — never disconnect the catheter junction.

Urine Dipstick Analysis

Point-of-care urine dipstick testing provides rapid results for nitrites (produced by Gram-negative bacteria, notably E. coli) and leucocyte esterase (a marker of pyuria). In symptomatic, non-pregnant women, the combination has a negative predictive value >90% and a negative result can reliably exclude UTI.

Essential Nitrites Sensitivity 45–60%, specificity 85–98%. Positive only if organisms produce nitrate reductase (most Gram-negatives). False negatives: short bladder dwell time (<4 hours), high dietary vitamin C, Pseudomonas (does not reduce nitrate). MBS item 73817 (urinalysis) — no separate MBS item for dipstick in GP; bundled into consultation.
Essential Leucocyte esterase (LE) Sensitivity 75–96%, specificity 65–94%. Marker of pyuria. False negatives: tetracycline, high vitamin C. False positives: vaginal contamination, interstitial nephritis.
Available Blood (haematuria) Microscopic haematuria is common in UTI. Persistent haematuria after UTI resolution warrants investigation for malignancy (≥40 years) or glomerular disease.
Dipstick Result Interpretation Action
Nitrites + and/or LE + Likely UTI in symptomatic patient Treat empirically (uncomplicated); send culture if complicated/recurrent
Nitrites − and LE − UTI very unlikely in low-risk symptomatic woman Do NOT treat — consider alternative diagnoses; send culture if clinical suspicion remains
Nitrites − and LE + Possible UTI or contamination; consider alternative causes Send MSU for culture; treat if high clinical suspicion; consider STI if sexually active
Nitrites + and LE − Possible UTI with insufficient dwell time Send MSU; treat if symptomatic; request first-morning specimen if possible

Urine Culture

MSU culture and sensitivity (C&S) is the diagnostic gold standard. Results typically available within 24–48 hours. Colony counts and significance thresholds depend on clinical context:

Specimen Type Significant Colony Count MBS Item
Midstream urine (MSU) ≥10⁵ CFU/mL (single organism); ≥10⁴ may be significant if symptomatic MBS 69314 — microscopy, culture & sensitivity
Suprapubic aspirate (SPA) Any growth is significant MBS 69314
Catheter specimen ≥10⁵ CFU/mL with symptoms (colonisation alone is expected and does NOT require treatment) MBS 69314
Paediatric clean-catch / bag ≥10⁵ CFU/mL (bag specimens have higher contamination — correlate clinically) MBS 69314

When to Send Culture (vs Treat Empirically)

📋
  • Empirical treatment acceptable (no culture needed): Uncomplicated cystitis in non-pregnant pre-menopausal women with classic symptoms and positive dipstick.
  • Culture ALWAYS required: All pregnant women; all children; all males; pyelonephritis; catheterised patients; treatment failure or relapse; recurrent UTI (≥3/year); immunosuppressed patients; urological abnormalities; suspected CAUTI; urosepsis/sepsis.

Additional Investigations

Available Blood cultures MBS 69315. Indicated in pyelonephritis with systemic features (fever >38.5°C, rigors, hypotension), urosepsis, and all immunosuppressed patients. Positive in 20–30% of pyelonephritis cases.
Available Full blood count (FBC) MBS 66503. Leucocytosis supports diagnosis in complicated UTI; leucopenia may indicate overwhelming sepsis.
Available Serum creatinine, eGFR, electrolytes MBS 66515. Essential in pyelonephritis and urosepsis to assess renal function and guide antibiotic dosing.
Available C-reactive protein (CRP) MBS 66549. Helpful to differentiate lower from upper UTI; CRP >50 mg/L strongly suggests pyelonephritis.
Referral Renal tract ultrasound MBS 55038. Indicated in recurrent UTI, pyelonephritis not responding to 48–72 h treatment, suspected obstruction (stone, tumour), children <3 years with first UTI, and ATSI patients with recurrent infections.
Specialist CT abdomen/pelvis with contrast MBS 56001/56007. For suspected renal abscess, emphysematous pyelonephritis, or complicated urolithiasis. Typically ordered by urologist or via ED.

Management in Non-Pregnant Adults

Uncomplicated Cystitis

Management of uncomplicated cystitis in non-pregnant women is primarily empirical and does not require urine culture in typical presentations with positive dipstick. Short-course antibiotics are effective, minimise collateral antimicrobial resistance, and reduce side effects.

⚠️
Antimicrobial resistance alert: Trimethoprim resistance in community E. coli now exceeds 20% in many Australian regions. Check local antibiogram data before prescribing. If trimethoprim resistance is >20% locally, prefer nitrofurantoin. Avoid fluoroquinolones (ciprofloxacin, norfloxacin) as first-line for uncomplicated UTI — they are reserved for more serious infections per AMS principles.

First-Line Agents — Uncomplicated Cystitis

💊
Nitrofurantoin (Macrobid®)
Nitrofurantoin macrocrystals · Urinary antiseptic
Adult dose 100 mg PO BD (modified-release) or 50 mg PO QDS (macrocrystals)
Duration 5 days (modified-release) or 5–7 days (macrocrystals)
Route Oral
Renal adjustment Contraindicated if eGFR <45 mL/min (ineffective and risk of pulmonary toxicity)
Hepatic adjustment Contraindicated in hepatic impairment
Key notes Concentrates in urine only — not suitable for pyelonephritis. Avoid at term pregnancy (≥36 weeks). GI side effects common; take with food.
PBS status ✔ PBS General Benefit
💊
Trimethoprim
Alprim® · Apo-Trimethoprim® · Folate inhibitor
Adult dose 300 mg PO nocte (once daily at bedtime)
Duration 3 days
Route Oral
Renal adjustment Use with caution if eGFR <30 mL/min; dose reduction may be required. Specialist advice recommended.
Hepatic adjustment No specific adjustment; avoid in severe hepatic disease
Key notes Avoid if local E. coli resistance >20%. Risk of hyperkalaemia — check potassium if on ACEi/ARB/Spironolactone. Avoid in first trimester (folate antagonist). Avoid if sulphonamide allergy.
PBS status ✔ PBS General Benefit

Second-Line / Alternative Agents

💊
Cefalexin
Keflex® · Cephalosporin (1st generation)
Adult dose 500 mg PO BD
Duration 5–7 days
Renal adjustment Reduce dose if eGFR <30 mL/min (e.g., 500 mg daily or 250 mg BD)
Key notes Suitable in pregnancy. Avoid if anaphylaxis to penicillin (~2% cross-reactivity); use with caution if non-anaphylactic penicillin allergy.
PBS status ✔ PBS General Benefit
💊
Amoxicillin-Clavulanate
Augmentin® · Co-amoxiclav · Penicillin + β-lactamase inhibitor
Adult dose 500/125 mg PO TDS or 875/125 mg PO BD
Duration 5–7 days
Renal adjustment Reduce dose if eGFR 10–30 mL/min; avoid if eGFR <10 mL/min
Key notes Useful when E. coli resistance to trimethoprim and nitrofurantoin exists. High rate of diarrhoea. Available in pregnancy.
PBS status ✔ PBS General Benefit

Complicated UTI in Males

All UTIs in males are considered complicated by definition. A urine culture is mandatory. Treat empirically with cefalexin 500 mg PO BD or amoxicillin-clavulanate 500/125 mg PO TDS while awaiting sensitivities; adjust to culture-directed therapy. Treatment duration is 7–14 days. Consider prostatitis if symptoms persist beyond 7 days (requires 2–4 weeks of fluoroquinolone or trimethoprim with good prostatic penetration). Refer for urological assessment if recurrent.

Acute Pyelonephritis

Patients with pyelonephritis who are haemodynamically stable, tolerating oral fluids, and have reliable follow-up can be managed as outpatients with oral antibiotics. Those with systemic features (vomiting, rigors, hypotension, sepsis markers) require admission for intravenous therapy.

Outpatient Pyelonephritis — Oral Regimen

💊
Cefalexin
Keflex® · First-line oral for pyelonephritis
Adult dose 500 mg PO BD–TDS
Duration 7–14 days (total course including IV step-down)
PBS status ✔ PBS General Benefit
💊
Ciprofloxacin
Ciproxin® · Fluoroquinolone (reserved agent)
Adult dose 500 mg PO BD
Duration 7 days
Key notes Reserve for confirmed or strongly suspected Gram-negative infection resistant to other agents. Avoid in pregnancy. Risk of tendon rupture (esp. with corticosteroids, >60 years). Do NOT use for uncomplicated cystitis.
PBS status ⚠ PBS Authority Required

Inpatient Pyelonephritis — IV Regimen

💊
Ceftriaxone
Rocephin® · 3rd-generation cephalosporin
Adult dose 1–2 g IV daily
Duration IV until clinically improved (usually 48–72 h), then step down to oral cefalexin or ciprofloxacin to complete 10–14 days total
Key notes First-line IV for community-acquired pyelonephritis. No renal dose adjustment. Avoid in neonates (biliary sludging).
PBS status ⚠ PBS Authority Required (hospital use)
💊
Gentamicin
Garamycin® · Aminoglycoside
Adult dose 4–5 mg/kg IV once daily (extended-interval dosing)
Duration Short course (2–3 days) as empirical adjunct; step down as soon as C&S available
Renal adjustment Dose to ideal body weight; adjust interval based on therapeutic drug monitoring (trough levels). Requires daily monitoring of creatinine.
Key notes Use in urosepsis for Gram-negative cover. Monitor renal function and drug levels (aim trough <1 mg/L). Risk of nephrotoxicity and ototoxicity.
PBS status ✔ PBS General Benefit (hospital)
🚨
Urosepsis: Patients meeting sepsis criteria require immediate resuscitation, blood cultures, lactate measurement, and broad-spectrum IV antibiotics within 1 hour of recognition. Empirical regimen: ceftriaxone 2 g IV + gentamicin 5 mg/kg IV (adjust for renal function). Add vancomycin if ESBL-producing organism suspected or patient has healthcare-associated risk factors. Escalate to piperacillin-tazobactam or meropenem if no clinical improvement by 48 hours. Contact ICU early.

Asymptomatic Bacteriuria

Treatment of ASB is one of the most common causes of unnecessary antibiotic prescribing in Australian healthcare. The following rules apply:

✅
  • TREAT ASB: Pregnant women (all trimesters); patients undergoing urological procedures (treat pre-procedure, culture-guided).
  • DO NOT TREAT ASB: Non-pregnant women; men; catheterised patients (bacteriuria is universal); elderly in residential care; patients with diabetes; spinal cord injury patients; renal transplant recipients (controversial — follow transplant unit protocol).

Management in Pregnant Women, Children & Recurrent UTI

Urinary Tract Infection in Pregnancy

UTI in pregnancy carries significant maternal and fetal risks including preterm labour, low birth weight, perinatal mortality, and maternal pyelonephritis. All pregnant women with symptomatic UTI or asymptomatic bacteriuria must be treated promptly.

⚠️
Key differences in pregnancy: Asymptomatic bacteriuria MUST be treated (risk of pyelonephritis 20–40% if untreated). MSU culture is mandatory for every suspected UTI. Urine dipstick alone is insufficient due to altered physiology (glucosuria, proteinuria). Avoid trimethoprim in first trimester (folate antagonist) and at term (risk of neonatal hyperbilirubinaemia). Avoid fluoroquinolones throughout pregnancy. Avoid nitrofurantoin at ≥36 weeks (neonatal haemolytic anaemia risk).

Antibiotics for UTI in Pregnancy

💊
Amoxicillin
Amoxil® · Penicillin
Adult dose 500 mg PO TDS
Duration ASB: 5–7 days · Symptomatic UTI: 7 days · Pyelonephritis: 10–14 days
Pregnancy category Category A (safe in all trimesters)
Key notes First-line for ASB. Use only if C&S confirms sensitivity — resistance rates are high (~40% for E. coli). If resistant, use cefalexin.
PBS status ✔ PBS General Benefit
💊
Cefalexin
Keflex® · First-generation cephalosporin
Adult dose 500 mg PO BD–TDS
Duration ASB: 5–7 days · Symptomatic UTI: 7 days · Pyelonephritis: 10–14 days
Pregnancy category Category A
Key notes Preferred first-line for empirical treatment in areas with high amoxicillin resistance. Generally well tolerated.
PBS status ✔ PBS General Benefit
💊
Nitrofurantoin
Macrobid® · Urinary antiseptic
Adult dose 100 mg PO BD (modified-release) or 50 mg PO QDS
Duration 5–7 days
Pregnancy category Category B2 — acceptable in 1st and 2nd trimesters; AVOID from ≥36 weeks gestation
Key notes Effective if C&S shows sensitivity. Avoid at term due to risk of neonatal haemolytic anaemia. Avoid in G6PD deficiency.
PBS status ✔ PBS General Benefit

Follow-up urine culture 1–2 weeks after completing treatment is mandatory in all pregnant women to confirm eradication. Repeat screening each trimester for women with a history of ASB or UTI.

Urinary Tract Infection in Children

UTI is the most common serious bacterial infection in childhood, affecting approximately 8% of girls and 2% of boys by age 7 years. Diagnosis in pre-verbal children is challenging, and delayed treatment risks renal scarring.

📋
Paediatric diagnosis: In children not yet toilet-trained, suprapubic aspirate (SPA) is the gold standard (any growth significant). Clean-catch midstream urine is preferred in toilet-trained children. Bag urine specimens have high false-positive rates — if bag urine is positive, confirm with MSU or SPA before initiating treatment.

Paediatric Antibiotics

💊
Trimethoprim
Alprim® · First-line oral for paediatric UTI
Paediatric dose <6 months: 2 mg/kg BD · 6 months–12 years: 4 mg/kg BD (max 200 mg/dose)
Duration Lower UTI: 3–5 days · Upper UTI: 7–10 days
Key notes Palatable suspension available. Wait for culture result in non-toxic child if possible. Adjust based on sensitivities.
PBS status ✔ PBS General Benefit
💊
Cefalexin
Keflex® · Alternative first-line
Paediatric dose 12.5–25 mg/kg PO BD–TDS (max 500 mg/dose)
Duration Lower UTI: 5–7 days · Upper UTI: 7–10 days
Key notes Useful when trimethoprim resistance suspected or patient has sulphonamide allergy. Palatable suspension available.
PBS status ✔ PBS General Benefit

Paediatric Imaging Recommendations

Paediatric imaging aims to identify structural abnormalities predisposing to recurrent UTI and renal scarring. Recommendations follow RCH Melbourne and Kidney Health Australia guidelines:

Age / Presentation Recommended Imaging Timing
First UTI, <3 years, typical and responds to treatment Renal tract ultrasound (US) Within 6 weeks (not urgent)
First UTI, <3 years, atypical (recurrent, poor response, sepsis, raised creatinine, non-E. coli) US + DMSA scan (at 4–6 months post-infection for scarring) ± MCU US during acute illness; DMSA at 4–6 months; MCU if VUR suspected
First UTI, ≥3 years, typical and responds No routine imaging required N/A — observe
Recurrent UTI (any age) US ± DMSA ± MCU Discuss with paediatric nephrologist/urologist
Unwell child with suspected obstruction US urgently Immediately

Recurrent UTI

Recurrent UTI is defined as ≥3 episodes of symptomatic UTI in 12 months or ≥2 episodes in 6 months. It affects approximately 20–30% of women with a first UTI and warrants investigation for underlying predisposing factors and discussion of preventive strategies.

Investigation of Recurrent UTI

1
Confirm true recurrence
Ensure each episode has positive culture (≥10⁵ CFU/mL) with symptoms. Distinguish recurrence (new infection) from relapse (same organism, incomplete treatment) and reinfection (different organism).
2
Identify risk factors
Assess sexual activity patterns (post-coital prophylaxis), contraception (spermicide use), menopausal status (vaginal atrophy), voiding habits, constipation, fluid intake, and family history.
3
Renal tract ultrasound
To exclude structural abnormalities — hydronephrosis, calculi, polycystic kidneys, bladder pathology. In males, always consider prostate assessment.
4
Consider urology referral
Refer for recurrent pyelonephritis, suspected obstruction, recurrent UTI in males, suspected interstitial cystitis, or failure of prophylactic measures. May perform cystoscopy or urodynamics.

Non-Antibiotic Prevention Strategies

Intervention Evidence & Notes
Increased fluid intake (≥1.5 L/day) RCT evidence of ~50% reduction in recurrence. Low cost, no harm. Recommend to all patients.
Post-coital voiding Weak evidence but widely recommended; low risk. Advise voiding within 30 minutes of intercourse.
Cranberry products Modest evidence for reduction (NNT ~7–8 in women with recurrent UTI). Consider as adjunct; avoid in patients on warfarin (INR interaction).
Topical vaginal oestrogen (postmenopausal) Strong evidence (RR 0.42). Restores Lactobacillus flora. PBS-listed for urogenital atrophy. Use cream or pessary 2–3 times/week.
D-mannose Emerging evidence (small RCTs suggest benefit comparable to nitrofurantoin prophylaxis). 2 g daily. Not PBS-listed; available OTC.
Avoid spermicides Strong association with recurrent UTI. Recommend alternative contraception.
Treat constipation Constipation impairs bladder emptying — particularly relevant in children. Ensure regular bowel habits.

Antibiotic Prophylaxis for Recurrent UTI

📋
When to consider prophylaxis: After discussion of non-antibiotic measures, consider low-dose prophylaxis for patients with ≥3 UTIs in 12 months despite behavioural interventions. The benefit must be weighed against antimicrobial resistance development.
💊
Trimethoprim (prophylactic dose)
Alprim® · Continuous prophylaxis
Adult dose 150 mg PO nocte
Duration 3–6 months; review at 6 months
Key notes Most commonly used prophylactic agent in Australia. Monitor for resistance with repeat cultures.
PBS status ✔ PBS General Benefit
💊
Nitrofurantoin (prophylactic dose)
Macrobid® · Alternative continuous prophylaxis
Adult dose 50–100 mg PO nocte
Duration 3–6 months; review
Renal adjustment Contraindicated if eGFR <45 mL/min
Key notes Alternative when trimethoprim resistance or intolerance. Monitor for pulmonary toxicity with prolonged use.
PBS status ✔ PBS General Benefit
💊
Post-coital prophylaxis
For UTI temporally linked to intercourse
Regimen Trimethoprim 150 mg or nitrofurantoin 50–100 mg PO — single dose taken within 2 hours of intercourse
Duration Indefinite (review 6-monthly)
Key notes Preferred over continuous prophylaxis when UTIs are temporally linked to sexual activity. Lower total antibiotic exposure.
PBS status ✔ PBS General Benefit

Special Populations

👶 Paediatrics
All suspected UTIs in children require urine culture before treatment (dipstick alone is insufficient).
SPA is gold standard in non-toilet-trained children; clean-catch MSU if toilet-trained.
Avoid fluoroquinolones in children (cartilage toxicity) except in specific circumstances under specialist guidance.
Consider vesicoureteric reflux (VUR) in children with recurrent UTI — micturating cystourethrogram (MCU) may be indicated.
First-line: Trimethoprim 4 mg/kg BD or Cefalexin 12.5–25 mg/kg BD–TDS
Duration: 3–5 days (cystitis) or 7–10 days (pyelonephritis). Always review culture and adjust.
👴 Elderly (≥65 years)
Asymptomatic bacteriuria is extremely common (20–50% in residential aged care) — do NOT treat unless symptomatic.
Classic urinary symptoms may be absent; new confusion, functional decline, falls, incontinence, or fever may be the only indicators.
Avoid nitrofurantoin if eGFR <45 mL/min (common in elderly).
Be cautious with trimethoprim + ACEi/ARB/Spironolactone (hyperkalaemia risk).
Catheterised residents: treat only if symptomatic (fever, rigors, new confusion). Change catheter before starting antibiotics.
Preferred: Cefalexin 500 mg BD (if eGFR permits) or trimethoprim 150 mg nocte
Dehydration is a major risk factor — ensure adequate fluid intake in aged care settings.
🫘 Renal Impairment
Nitrofurantoin is CONTRAINDICATED if eGFR <45 mL/min — ineffective (insufficient urinary concentration) and risk of peripheral neuropathy.
Trimethoprim: use with caution if eGFR <30 mL/min; consider dose reduction.
Cefalexin: reduce dose if eGFR <30 mL/min.
Gentamicin: requires therapeutic drug monitoring; extended-interval dosing with dose adjusted to renal function.
Preferred agents: Cefalexin (dose-adjusted) or amoxicillin-clavulanate
Always check eGFR before prescribing UTI antibiotics. Avoid nephrotoxic agents where possible.
🫀 Hepatic Impairment
Nitrofurantoin is contraindicated in hepatic impairment (hepatotoxicity risk).
Trimethoprim: no significant hepatic metabolism; generally safe.
Cefalexin: no dose adjustment (renal elimination).
Preferred: Cefalexin or trimethoprim
Monitor LFTs if nitrofurantoin inadvertently used.
🛡️ Immunocompromised
UTI in immunocompromised patients (transplant recipients, chemotherapy-induced neutropenia, HIV with low CD4, high-dose corticosteroids) is always complicated and requires urine culture.
Broader empirical antibiotic cover may be warranted; consider ceftriaxone IV or piperacillin-tazobactam if sepsis suspected.
Renal transplant recipients: UTI is a significant cause of graft dysfunction; refer to transplant unit.
Febrile neutropenia with UTI: treat as per institutional febrile neutropenia protocol (broad-spectrum IV antibiotics).
Empirical: Ceftriaxone 1–2 g IV daily ± gentamicin; adjust per C&S
Low threshold for hospital admission. Discuss with infectious diseases team.
Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Australians experience a significantly higher burden of urinary tract infections compared to non-Indigenous Australians. AIHW data demonstrate 2.0–3.1 times higher hospitalisation rates for UTI among Indigenous Australians, with the disparity greatest in remote and very remote communities. Chronic kidney disease prevalence is 2–3 times higher in the ATSI population, and recurrent UTI is a contributing factor to renal scarring and progression to end-stage kidney disease.

Remote access to diagnostics
MSU culture requires specimen transport to regional laboratories (24–72 hours in remote communities). Point-of-care urinalysis (dipstick) is available in most Aboriginal Community Controlled Health Organisations (ACCHOs) and should be used to guide empirical treatment while awaiting culture. The use of urine collection bags is culturally inappropriate for some communities — clean-catch technique should be taught with cultural sensitivity.
Antimicrobial resistance
ESBL-producing E. coli rates are higher in remote ATSI communities (up to 20–25% in some NT and QLD data). CA-MRSA is also more prevalent. Empirical antibiotic selection must account for local antibiograms. Communicate with regional microbiology services for up-to-date resistance patterns.
Social determinants
Overcrowded housing, limited access to clean water and sanitation, and reduced access to functioning toilet facilities in some remote communities contribute to UTI risk. Health promotion activities should be delivered in partnership with ACCHOs using culturally safe messaging in local languages.
Chronic disease intersection
High rates of diabetes in ATSI communities increase UTI susceptibility. The combination of diabetes, recurrent UTI, and chronic kidney disease requires integrated chronic disease management through ACCHOs and Aboriginal health workers.
Cultural safety
Urine collection may be culturally sensitive, particularly for women and children. Use same-gender health workers where possible. Understand that some patients may prefer traditional healing alongside biomedical treatment — engage respectfully with these preferences. Avoid paternalistic language; use strengths-based health literacy approaches.
Follow-up and continuity
Follow-up culture (mandatory in pregnancy) is challenging in mobile populations. Use recall systems, text message reminders, and Aboriginal health worker outreach. Ensure culture results are actioned even if the patient has returned to a remote community — telehealth follow-up with a GP or specialist is recommended.
⚠️
Key recommendation: For ATSI patients with recurrent UTI, always perform renal tract ultrasound to assess for structural abnormalities and renal scarring. Ensure screening and management of concurrent diabetes, as glycaemic control significantly impacts UTI recurrence. Partner with local ACCHOs and Aboriginal health workers for culturally safe care delivery, chronic disease management, and health promotion.

Quick Reference — Empirical Antibiotic Guide

Uncomplicated cystitis (woman)
Nitrofurantoin 100 mg BD
5 days
Or trimethoprim 300 mg nocte × 3 days if local resistance <20%
Complicated cystitis (male)
Cefalexin 500 mg BD
7–14 days
Culture mandatory; adjust per C&S
Pyelonephritis (outpatient)
Cefalexin 500 mg BD–TDS
7–14 days
Or ciprofloxacin 500 mg BD × 7 days if resistant
Pyelonephritis (inpatient)
Ceftriaxone 1–2 g IV daily
IV 48–72 h → oral step-down
Add gentamicin if urosepsis; total 10–14 days
UTI in pregnancy
Cefalexin 500 mg BD or amoxicillin 500 mg TDS
7 days (symptomatic); 5–7 days (ASB)
Mandatory follow-up culture at 1–2 weeks post-treatment
Paediatric UTI
Trimethoprim 4 mg/kg BD or cefalexin 12.5–25 mg/kg BD
3–5 days (cystitis); 7–10 days (pyelonephritis)
Culture mandatory; imaging per guidelines
Recurrent UTI prophylaxis
Trimethoprim 150 mg nocte
3–6 months
Or nitrofurantoin 50–100 mg nocte; consider post-coital regimen

📚 References

  1. 1. Australian Commission on Safety and Quality in Health Care (ACSQHC). Australian Atlas of Healthcare Variation — Urinary Tract Infections. Sydney: ACSQHC; 2018.
  2. 2. Australian Institute of Health and Welfare (AIHW). Admitted patient care 2021–22: Urinary tract infections. AIHW; 2023.
  3. 3. National Health and Medical Research Council (NHMRC). Antimicrobial prescribing guidelines: Urinary tract infection. Canberra: NHMRC; 2020.
  4. 4. Grabe M, Bjerklund-Johansen TE, Bartoletti R, et al. EAU Guidelines on Urological Infections. European Association of Urology; 2023.
  5. 5. Kidney Health Australia. Chronic Kidney Disease Management in Primary Care. 4th ed. Melbourne: Kidney Health Australia; 2020.
  6. 6. Royal Children's Hospital Melbourne. Clinical Practice Guidelines: Urinary Tract Infection. Melbourne: RCH; 2023. Available from: https://www.rch.org.au/clinicalguide/guideline_index/Urinary_Tract_Infection/
  7. 7. Australian Commission on Safety and Quality in Health Care (ACSQHC). Australian National Antimicrobial Resistance Strategy 2020–2030. Canberra: Commonwealth of Australia; 2020.
  8. 8. Hooton TM, Vecchio M, Iroz A, et al. Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial. JAMA Intern Med. 2018;178(11):1509–1515.
  9. 9. Juthani-Mehta M, Van Ness PH, Bianco L, et al. Effect of cranberry capsules on bacteriuria plus pyuria among older women in nursing homes: a randomized clinical trial. JAMA. 2016;316(18):1879–1887.
  10. 10. Subramanian V, Batura N, Opondo C, et al. Cost-effectiveness of prophylactic antibiotics for recurrent urinary tract infections in women. BMJ Open. 2023;13(1):e064567.
  11. 11. Australian Indigenous HealthInfoNet. Kidney health: Aboriginal and Torres Strait Islander people. Perth: Edith Cowan University; 2023.
  12. 12. Guglielminotti J, Dehlendorff C, Friis S, et al. Risk factors for catheter-associated urinary tract infections: a systematic review and meta-analysis. J Hosp Infect. 2023;131:59–69.
  13. 13. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1–13.
  14. 14. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–e120.
  15. 15. Office of Health Protection, Australian Government Department of Health. Antimicrobial Use and Resistance in Australia (AURA) Surveillance System Report 2023. Canberra: Commonwealth of Australia; 2023.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).